Back to search

National and Kapodistrian University of Athens

Preoperative radiotherapy in rectal cancer and immune response

Abstract

dc:description

Background-Introduction: Neoadjuvant radiotherapy (RT) is a primary therapeutic modality for the treatment of locally advanced rectal cancer. Recent advances in immunotherapy for rectal cancer suggest that the immune system plays a significant role in the control of this malignancy. Experimental research has demonstrated that RT has both immunosuppressive and immunostimulatory properties. Specifically for rectal cancer, a number of studies have demonstrated a direct effect of RT and chemo-radiotherapy (CRT) on immune checkpoint molecules expression by cancer cells, and on the quantity and quality of lymphocytes and monocytes invading irradiated rectal cancer tissue. Optimal combination of immunotherapy with RT is still under investigation. Materials and Methods: Retrospective clinical study: Thirty-three (33) rectal adenocarcinoma patients treated with preoperative long-course CRT (lcRT) were analyzed. The primary objective was to assess the effects of CRT on the lymphocyte counts (LC) of the peripheral blood, and the potential impact of CRT-induced lymphopenia on tumor response and patient prognosis. Prospective clinical-laboratory study: An ELISA assay was performed to analyze the IFNβ plasma levels of patients with rectal adenocarcinoma, before and after treatment with short-course RT (scRT) (n=22) and lcRT (n=40). Patient LC were also recorded before and after RT. Moreover, flow cytometry was utilized in order to assess RT’s effect on the peripheral T-cell subpopulations (CD4+, CD8+, CD25+, FOXP3+ T-cells) in 20 patients (10 patients from each cohort). Immunohistochemical and in vitro study: Immunohistochemistry was conducted, aiming to study the expression of HLA-class-I, β2-microglobulin, TAP-1, PD-L1 and STING/IFNβ in preoperative biopsies and respective post-CRT (lcRT) surgical specimens from 27 rectal adenocarcinoma patients. The human colorectal adenocarcinoma cell lines HT-29 and Caco-2 were used in order to further investigate RT’s effects; Western blot analysis and Real time PCR (RT-PCR) were performed. Results: Retrospective clinical study: The LC of patients were significantly decreased post-treatment with CRT (median values: 2184/μl and 517/μl before and after treatment, respectively; p<0.0001). A statistically significant correlation was noted between poor tumor regression grade (TRG) and lower LC (p=0.03). No association between ypT-stage or ypN status and LC was confirmed. Furthermore, lymphopenia was significantly linked with poorer distant metastasis-free survival (p=0.003). No patient (0%) with LC above 518/μl developed distant metastases vs. 44.5% of patients with lower LC values. Prospective clinical-laboratory study: The IFNβ plasma levels of patients after scRT were significantly increased (p=0.004). Enhanced post-RT IFNβ levels were associated with improved pathological tumor regression (p=0.003). Substantial lymphopenia was recorded in all patients after treatment completion. However, patients treated with scRT displayed significantly higher post-RT LC compared to lcRT patients (p=0.001). Although no marked effect of RT on the percentages of CD4+ and CD8+ T-cells was demonstrated with either treatment schedule, the absolute LC of CD8+ T-cells post-RT were marginally higher in the scRT group (p=0.07). Finally, it was shown that patients treated with lcRT had significantly higher percentages of regulatory CD4+/CD25+ T-cells after treatment (p=0.02). Immunohistochemical and in vitro study: Rectal carcinomas exhibited extensive loss of HLA-class-I related molecules expression, which was restored in post-irradiation surgical specimens (p<0.0001). IFNβ and STING were significantly induced in both cancer cells and tumor-infiltrating lymphocytes after RT (p<0.0001). In cancer cell line experiments, upregulation of the HLA-class-I protein was confirmed after 4 or 10 Gy irradiation (p<0.001). PD-L1 levels were transiently induced for two days (p<0.001). Three fractions of 8 Gy or 1 fraction of 20 Gy led to a significant increase of the mRNA levels of cGAS, STING, IFNβ and the downstream genes (MX1, MX2, UBE2L6v2, IFI6v2 and IFI44) (p<0.001). No effects of RT on TREX1 mRNA levels were observed. Conclusions: Rectal adenocarcinoma patients experience substantial lymphopenia after neoadjuvant RT, with subsequent implications on tumor response and prognosis. scRT, however, appears to confer lesser lymphotoxicity, limited regulatory T-cell activation and potent IFN-type-I pathway stimulation compared to lcRT. Moreover, HLA-class-I molecules expression and IFNβ/STING proteins are significantly upregulated in cancer cells after RT. The transient induction of PD-L1 expression suggests that lcRT may sustain increased PD-L1 levels. Anti-PD-L1/PD-1 immunotherapy could block this immunosuppressive pathway. Overall, our findings confirm a significant interplay between RT and the immune system, that could be exploited in immuno-RT trials for patients with rectal adenocarcinomas. Hypofractionated RT (scRT) could prove to be key in enhancing immunotherapy efficacy.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2024

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Koukourakis, Ioannis
  • Κουκουράκης, Ιωάννης

Subjects

dc:subject × 16

Rights

Language dc:language
eng

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/56996

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Koukourakis, Ioannis; Κουκουράκης, Ιωάννης. Preoperative radiotherapy in rectal cancer and immune response. National and Kapodistrian University of Athens, 2024. http://hdl.handle.net/10442/hedi/56996